222 related articles for article (PubMed ID: 30535366)
1. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
Decloedt EH; Sinxadi PZ; van Zyl GU; Wiesner L; Khoo S; Joska JA; Haas DW; Maartens G
J Antimicrob Chemother; 2019 Mar; 74(3):699-709. PubMed ID: 30535366
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid.
Decloedt EH; Sinxadi PZ; Wiesner L; Joska JA; Haas DW; Maartens G
South Afr J HIV Med; 2021; 22(1):1206. PubMed ID: 34007475
[TBL] [Abstract][Full Text] [Related]
6. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
[TBL] [Abstract][Full Text] [Related]
7. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
[TBL] [Abstract][Full Text] [Related]
9. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
[TBL] [Abstract][Full Text] [Related]
14. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
15. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
de Almeida TB; de Azevedo MCVM; Pinto JFDC; Ferry FRA; da Silva GAR; de Castro IJ; Baker P; Tanuri A; Haas DW; Cardoso CC
J Antimicrob Chemother; 2018 Sep; 73(9):2460-2467. PubMed ID: 29868865
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
[TBL] [Abstract][Full Text] [Related]
17. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
Torgersen J; Bellamy SL; Ratshaa B; Han X; Mosepele M; Zuppa AF; Vujkovic M; Steenhoff AP; Bisson GP; Gross R
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):179-187. PubMed ID: 30168000
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China.
Chen R; Chen J; Xun J; Hu Z; Huang Q; Zhang R; Steinhart C; Shen Y; Liu L; Lu H
Pharmacogenomics; 2020 Aug; 21(13):945-956. PubMed ID: 32838647
[No Abstract] [Full Text] [Related]
19. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
